Skip to main content

Table 1 Evolving roles alters the immunometabolism of cancer cell survival and growth

From: Cancer immunometabolism: advent, challenges, and perspective

Metabolites

Target immune cell

Mediators

Effects on immunity

Outcomes

Refer to Refs.

Glu

Treg cell

mGlutR1

Enhancement of Treg proliferation, activation, and immunosuppression

Pro-cancer

[9]

FA

Treg cell

SREBP and FASN

SREBP combined with FASN promotes FA synthesis, which in turn promotes Treg maturation and drives immunosuppression

Pro-cancer

[11]

Inhibition of FASN reduces fat accumulation in hepatocytes and directly suppresses immune cells and stellate cells

Anti-cancer

[122]

CD8+ T cell

STAT3

The leptin-STAT3 axis increases oxidation of FAs within CD8+ T cells in breast cancer

Pro-cancer

[81]

CD36

CD36 mediated uptake of FA by CD8+ T cells, induced lipid peroxidation and ferroptosis, and led to reduced cytotoxic cytokine production

Pro-cancer

[161]

B cell

CD37

As essential membrane-localized inhibitor of FA metabolism, CD37 inhibits FATP1 (FA transporter) and subsequently leads to the inhibition of FA metabolism in aggressive B cell lymphomas

Anti-cancer

[162]

isoDCA

DCs and Treg cell

NR1H4; Foxp3

isoDCA inhibits the transcriptional activity of NR1H4 in DCs and attenuate the immunostimulatory properties of DCs, which in turn induces Foxp3 expression and Treg cell generation

Anti-cancer

[16]

Cholesterol

Neutrophil and CD8+ T cell

CXCR2

Depletion of toxic γδ-T cells promotes breast cancer metastasis

Pro-cancer

[23]

Tc9 cell

LXR

Cholesterol or its derivative oxysterols inhibited IL-9 expression by activating LXR Sumoylation-NF-κB signaling

Pro-cancer

[163]

Neutrophil

CXCR2

Recruiting neutrophils to achieve a state of local TME inhibition

Pro-cancer

[164]

HIF1α

Promoting angiogenesis in pancreatic neuroendocrine tumors

Pro-cancer

[165]

Leu

B cell

LARS2

LARS2 knockdown or leucine blockade reduces LARS2-expressing B-cell subpopulations, which in turn inhibits immune escape in colorectal cancer

Anti-cancer

[44]

Arg

CD8+ T cell

ARG1

Extracellular ARG1could interact with cathepsin S and enhanced enzymatic activity at physiological pH, and NET-associated hARG1 suppresses T lymphocytes

Pro-cancer

[166]

PGE2

NK cell and cDC1

may be XCL1 and CCL5

Direct inhibition of NK cell survival and chemokine production that followed by downregulation of chemokine expression in cDC1

Pro-cancer

[96]

Lactate

Treg cell

MCT1

Upregulation of lactate metabolic pathways to maintain immune response

Anti-cancer

[98]

Cytotoxic T cell

SUCNR1

Lactate reduces PC activity, succinate secretion and SUCNR1 activation, which inhibits autocrine signaling in cytotoxic T cells

Pro-cancer

[102]

αKG

Macrophage

Jmjd3; NF-κB

Coordinates M2 type activation of macrophages; Impairment of the pro-inflammatory response of M1 macrophages

Pro-cancer

[95]

Glycerol

Memory CD8+ T cells

IL-7

IL-7 signaling induces glycerol uptake to promote triacylglycerol synthesis and FAO, thus supporting the longevity of memory CD8+ T cells

Anti-cancer

[167]

Trp

CD8+ T cell

I3A

L. reuteri promotes interferon-gamma-producing CD8+ T cells that thereby enhancing immune checkpoint inhibitor therapy

Anti-cancer

[60]

Asn

CD8+ T cell

NRF2

Asn restriction enhances the metabolic capacity and anti-tumor function of CD8+ T cells

Anti-cancer

[66]

  1. CXCR2 C-X-C motif chemokine receptor 2, FA Fatty acid, PGE2 Prostaglandin E2, HIF1α Hypoxia-inducible factor-1α, isoDCA 3β-hydroxydeoxycholic acid, DCs Dendritic cells, TME Tumor microenvironment, TANs Tumor-associated neutrophils, NK cell Natural killer cell, cDC1 Conventional type 1 dendritic cell, Tc9 cell IL-9-secreting CD8+ T cell, LXR Liver X receptor, Arg Arginine, ARG1 Arginase 1, NETs Neutrophil extracellular traps, hARG1 Human arginase 1, PC Pyruvate carboxylase, αKG α-ketoglutarate, NF-κB Nuclear factor-κB, I3A Indole-3-aldehyde, IFN-γ Interferon-gamma, Trp Tryptophan, Asn Asparagine, Glu Glutamate, Treg cell Regulatory T cell, mGlutR1 Metabotropic glutamate receptor 1, Leu Leucine, LARS2 Leucine-tRNA-synthase-2